Electronic Resource
Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
| العنوان: | Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. |
|---|---|
| المؤلفون: | Burger H.G., Koch K., Davis S.R., Goldstat R., Newman A., Berry K., Meredith I. |
| بيانات النشر: | Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom) United Kingdom 2012-10-19 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Background: Most studies examining the potential cardioprotective effects of postmenopausal estrogen have been undertaken in healthy women, with doses that may not be appropriate for long-term intervention. New low-dose estrogen-progestin regimens alleviate postmenopausal symptoms with a favorable side-effect profile; however, little is known of the impact of such regimens in women at increased risk of cardiovascular disease. Hence, we have evaluated the effects of low-dose oral estrogen-progestin therapy on serum lipoprotein lipids, brachial artery reactivity and fibrinogen in hypercholesterolemic postmenopausal women in direct comparison with the effects of pravastatin, a lipid-lowering agent known to reduce cardiovascular events in women. Method(s): In a randomized, double-blind, double-dummy, parallel trial, we studied the effects of continuous combined estrogen-progestin therapy (1 mg 17beta-estradiol with 500 mug norethisterone acetate daily) or pravastatin (20 mg daily) in 72 postmenopausal women with fasting serum low-density lipoprotein (LDL) cholesterol levels greater than 124 mg/dl after an 8-week run-in diet, over a 24-week period. The primary end-point was percentage change in LDL cholesterol from baseline. Result(s): The intention-to-treat population comprised 65 women, mean age 59 +/- 6.3 years, and 29 in each group completed the trial. Diet alone reduced LDL cholesterol significantly in both treatment groups, in association with a reduction in weight during this period. Compared with respective baseline values, pravastatin decreased LDL cholesterol and total cholesterol to a greater extent than hormone therapy (p = 0.0001 and 0.003 for difference between treatments, respectively). High-density lipoprotein (HDL) cholesterol levels decreased with hormone therapy, but did not change with pravastatin (p = 0.01). Lipoprotein(a) decreased significantly with hormone therapy only (-14%, 95% confidence interval (CI) -21 to -6%, p = 0.01 for difference between |
| مصطلحات الفهرس: | gastrointestinal symptom/si [Side Effect], heart infarction/si [Side Effect], heart protection, high risk patient, hormone substitution, human, hypercholesterolemia/dt [Drug Therapy], hypercholesterolemia/th [Therapy], lipoprotein blood level, long term care, major clinical study, mastalgia/si [Side Effect], postmenopause, priority journal, quality of life, questionnaire, randomized controlled trial, side effect/si [Side Effect], treatment outcome, weight reduction, cholesterol/ec [Endogenous Compound], estradiol plus norethisterone acetate/ae [Adverse Drug Reaction], estradiol plus norethisterone acetate/ct [Clinical Trial], estradiol plus norethisterone acetate/cm [Drug Comparison], estradiol plus norethisterone acetate/dt [Drug Therapy], estradiol plus norethisterone acetate/po [Oral Drug Administration], estradiol plus norethisterone acetate/pd [Pharmacology], fibrinogen/ec [Endogenous Compound], high density lipoprotein cholesterol/ec [Endogenous Compound], lipoprotein/ec [Endogenous Compound], low density lipoprotein cholesterol/ec [Endogenous Compound], pravastatin/ae [Adverse Drug Reaction], pravastatin/ct [Clinical Trial], pravastatin/cm [Drug Comparison], pravastatin/dt [Drug Therapy], pravastatin/pd [Pharmacology], triacylglycerol/ec [Endogenous Compound], controlled study, adult, aged, artery blood flow, artery diameter, artery dilatation, article, blood vessel reactivity, brachial artery, cardiovascular risk, cholesterol blood level, clinical trial, controlled clinical trial, correlation analysis, diet therapy, double blind procedure, drug effect, endothelium injury, female, fibrinogen blood level, Article |
| URL: | Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2012 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/33017 Climacteric. 5 (4) (pp 341-350), 2002. Date of Publication: December 2002. 1369-7137 https://repository.monashhealth.org/monashhealthjspui/handle/1/33017 12626213 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12626213] 36143353 (Davis, Goldstat, Newman, Burger, Meredith) Jean Hailes Foundation Research Unit, Clayton South, Vic., Australia (Berry) Department of Cardiology, Monash Medical Centre, Clayton, Vic., Australia (Koch) Novo Nordisk, Copenhagen, Denmark (Davis) Jean Hailes Foundation, PO Box 1108, Clayton South, Vic. 3169, Australia 1305131535 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305131535 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |